{"doi":"10.3390/ijms21165744","title":"Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation","abstract":"Cancer-associated adipocytes are known to cause inflammation, leading to cancer progression and metastasis. The clinicopathological and transcriptomic data from 2256 patients with breast cancer were obtained based on three cohorts: The Cancer Genome Atlas (TCGA), GSE25066, and a study by Yau et al. For the current study, we defined the adipocyte, which is calculated by utilizing a computational algorithm, xCell, as “intratumoral adipocyte”. These intratumoral adipocytes appropriately reflected mature adipocytes in a bulk tumor. The amount of intratumoral adipocytes demonstrated no relationship with survival. Intratumoral adipocyte-high tumors significantly enriched for metastasis and inflammation-related gene sets and are associated with a favorable tumor immune microenvironment, especially in the ER+/HER2- subtype. On the other hand, intratumoral adipocyte-low tumors significantly enriched for cell cycle and cell proliferation-related gene sets. Correspondingly, intratumoral adipocyte-low tumors are associated with advanced pathological grades and inversely correlated with MKI67 expression. In conclusion, a high amount of intratumoral adipocytes in breast cancer was associated with inflammation, metastatic pathways, cancer stemness, and favorable tumor immune microenvironment. However, a low amount of adipocytes was associated with a highly proliferative tumor in ER-positive breast cancer. This cancer biology may explain the reason why patient survival did not differ by the amount of adipocytes.","journal":"International Journal of Molecular Sciences","year":2020,"id":61579,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":56,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.8869,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":243272,"name":"Masanori Oshi","orcid":"0000-0002-1404-1570","position":1,"is_corresponding":false},{"id":325505,"name":"Eriko Katsuta","orcid":"0000-0001-5862-2919","position":2,"is_corresponding":false},{"id":243275,"name":"Li Yan","orcid":"0000-0002-4792-9998","position":3,"is_corresponding":false},{"id":255004,"name":"Jing Huang","orcid":"0000-0002-7163-5156","position":4,"is_corresponding":false},{"id":291636,"name":"Masayuki Nagahashi","orcid":"0000-0003-3462-253X","position":5,"is_corresponding":false},{"id":248067,"name":"Nobuhisa Matsuhashi","orcid":null,"position":6,"is_corresponding":false},{"id":244395,"name":"Manabu Futamura","orcid":"0000-0001-5622-8352","position":7,"is_corresponding":false},{"id":244396,"name":"Kazuhiro Yoshida","orcid":"0000-0003-1408-0104","position":8,"is_corresponding":false},{"id":243279,"name":"Kazuaki Takabe","orcid":"0000-0002-6435-4241","position":9,"is_corresponding":false},{"id":243274,"name":"Yoshihisa Tokumaru","orcid":"0000-0003-2481-7739","position":0,"is_corresponding":true}],"reference_count":70,"raw_metadata":null,"created_at":"2026-07-18T21:09:47.114172Z","pmid":"32796516","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}